Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers

Rifat Hasina, Nathan Mollberg, Ichiro Kawada, Karun Mutreja, Geetanjali Kanade, Soheil Yala, Mosmi Surati, Ren Liu, Xiuqing Li, Yue Zhou, Benjamin D. Ferguson, Vidya Nallasura, Kenneth S. Cohen, Elizabeth Hyjek, Jeffery Mueller, Rajani Kanteti, Essam El Hashani, Dorothy Kane, Yutaka Shimada, Mark W. LingenAliya N. Husain, Mitchell C. Posner, Irving Waxman, Victoria M. Villaflor, Mark K. Ferguson, Lyuba Varticovski, Everett E. Vokes, Parkash Gill, Ravi Salgia

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identi fi ed EPHB4 to be robustly overexpressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma, 82 adenocarcinoma, 25 dysplasia, 13 Barrett esophagus, and 25 adjacent or unrelated normal esophageal tissues were evaluated by immunohistochemistry. EPHB4 expression was signi ficantly higher in all the different histologic categories than in adjacent normal tissues. In 13 esophageal cancer cell lines, 3 of the 9 SCC cell lines and 2 of the 4 adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-nitroquinoline 1-oxide (4-NQO)-induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small-molecule inhibitor of EPHB4 decreased cell viability in a timeand dose-dependent manner in 3 of the 4 cell lines tested. The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12%- 40% closure in treated vs. 60%-80% in untreated), with decreased phosphorylation of various tyrosyl-containing proteins, EphB4, and its downstream target p125FAK. Finally, in a xenograft tumor model, an EPHB4 inhibitor abrogated tumor growth by approximately 60% compared with untreated control. EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers.

Original languageEnglish
Pages (from-to)184-194
Number of pages11
JournalCancer Research
Volume73
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Esophageal Neoplasms
Cell Line
Adenocarcinoma
4-Nitroquinoline-1-oxide
Barrett Esophagus
Gene Dosage
Tumor Cell Line
Heterografts
Small Interfering RNA
Cell Movement
Squamous Cell Carcinoma
Neoplasms
Cell Survival
Biomarkers
Immunohistochemistry
Phosphorylation
Incidence
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hasina, R., Mollberg, N., Kawada, I., Mutreja, K., Kanade, G., Yala, S., ... Salgia, R. (2013). Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research, 73(1), 184-194. https://doi.org/10.1158/0008-5472.CAN-12-0915

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. / Hasina, Rifat; Mollberg, Nathan; Kawada, Ichiro; Mutreja, Karun; Kanade, Geetanjali; Yala, Soheil; Surati, Mosmi; Liu, Ren; Li, Xiuqing; Zhou, Yue; Ferguson, Benjamin D.; Nallasura, Vidya; Cohen, Kenneth S.; Hyjek, Elizabeth; Mueller, Jeffery; Kanteti, Rajani; El Hashani, Essam; Kane, Dorothy; Shimada, Yutaka; Lingen, Mark W.; Husain, Aliya N.; Posner, Mitchell C.; Waxman, Irving; Villaflor, Victoria M.; Ferguson, Mark K.; Varticovski, Lyuba; Vokes, Everett E.; Gill, Parkash; Salgia, Ravi.

In: Cancer Research, Vol. 73, No. 1, 01.01.2013, p. 184-194.

Research output: Contribution to journalArticle

Hasina, R, Mollberg, N, Kawada, I, Mutreja, K, Kanade, G, Yala, S, Surati, M, Liu, R, Li, X, Zhou, Y, Ferguson, BD, Nallasura, V, Cohen, KS, Hyjek, E, Mueller, J, Kanteti, R, El Hashani, E, Kane, D, Shimada, Y, Lingen, MW, Husain, AN, Posner, MC, Waxman, I, Villaflor, VM, Ferguson, MK, Varticovski, L, Vokes, EE, Gill, P & Salgia, R 2013, 'Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers', Cancer Research, vol. 73, no. 1, pp. 184-194. https://doi.org/10.1158/0008-5472.CAN-12-0915
Hasina, Rifat ; Mollberg, Nathan ; Kawada, Ichiro ; Mutreja, Karun ; Kanade, Geetanjali ; Yala, Soheil ; Surati, Mosmi ; Liu, Ren ; Li, Xiuqing ; Zhou, Yue ; Ferguson, Benjamin D. ; Nallasura, Vidya ; Cohen, Kenneth S. ; Hyjek, Elizabeth ; Mueller, Jeffery ; Kanteti, Rajani ; El Hashani, Essam ; Kane, Dorothy ; Shimada, Yutaka ; Lingen, Mark W. ; Husain, Aliya N. ; Posner, Mitchell C. ; Waxman, Irving ; Villaflor, Victoria M. ; Ferguson, Mark K. ; Varticovski, Lyuba ; Vokes, Everett E. ; Gill, Parkash ; Salgia, Ravi. / Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. In: Cancer Research. 2013 ; Vol. 73, No. 1. pp. 184-194.
@article{5e36c56f47614c80a6df43ff96582fc5,
title = "Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers",
abstract = "Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identi fi ed EPHB4 to be robustly overexpressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma, 82 adenocarcinoma, 25 dysplasia, 13 Barrett esophagus, and 25 adjacent or unrelated normal esophageal tissues were evaluated by immunohistochemistry. EPHB4 expression was signi ficantly higher in all the different histologic categories than in adjacent normal tissues. In 13 esophageal cancer cell lines, 3 of the 9 SCC cell lines and 2 of the 4 adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-nitroquinoline 1-oxide (4-NQO)-induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small-molecule inhibitor of EPHB4 decreased cell viability in a timeand dose-dependent manner in 3 of the 4 cell lines tested. The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12{\%}- 40{\%} closure in treated vs. 60{\%}-80{\%} in untreated), with decreased phosphorylation of various tyrosyl-containing proteins, EphB4, and its downstream target p125FAK. Finally, in a xenograft tumor model, an EPHB4 inhibitor abrogated tumor growth by approximately 60{\%} compared with untreated control. EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers.",
author = "Rifat Hasina and Nathan Mollberg and Ichiro Kawada and Karun Mutreja and Geetanjali Kanade and Soheil Yala and Mosmi Surati and Ren Liu and Xiuqing Li and Yue Zhou and Ferguson, {Benjamin D.} and Vidya Nallasura and Cohen, {Kenneth S.} and Elizabeth Hyjek and Jeffery Mueller and Rajani Kanteti and {El Hashani}, Essam and Dorothy Kane and Yutaka Shimada and Lingen, {Mark W.} and Husain, {Aliya N.} and Posner, {Mitchell C.} and Irving Waxman and Villaflor, {Victoria M.} and Ferguson, {Mark K.} and Lyuba Varticovski and Vokes, {Everett E.} and Parkash Gill and Ravi Salgia",
year = "2013",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-12-0915",
language = "English",
volume = "73",
pages = "184--194",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers

AU - Hasina, Rifat

AU - Mollberg, Nathan

AU - Kawada, Ichiro

AU - Mutreja, Karun

AU - Kanade, Geetanjali

AU - Yala, Soheil

AU - Surati, Mosmi

AU - Liu, Ren

AU - Li, Xiuqing

AU - Zhou, Yue

AU - Ferguson, Benjamin D.

AU - Nallasura, Vidya

AU - Cohen, Kenneth S.

AU - Hyjek, Elizabeth

AU - Mueller, Jeffery

AU - Kanteti, Rajani

AU - El Hashani, Essam

AU - Kane, Dorothy

AU - Shimada, Yutaka

AU - Lingen, Mark W.

AU - Husain, Aliya N.

AU - Posner, Mitchell C.

AU - Waxman, Irving

AU - Villaflor, Victoria M.

AU - Ferguson, Mark K.

AU - Varticovski, Lyuba

AU - Vokes, Everett E.

AU - Gill, Parkash

AU - Salgia, Ravi

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identi fi ed EPHB4 to be robustly overexpressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma, 82 adenocarcinoma, 25 dysplasia, 13 Barrett esophagus, and 25 adjacent or unrelated normal esophageal tissues were evaluated by immunohistochemistry. EPHB4 expression was signi ficantly higher in all the different histologic categories than in adjacent normal tissues. In 13 esophageal cancer cell lines, 3 of the 9 SCC cell lines and 2 of the 4 adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-nitroquinoline 1-oxide (4-NQO)-induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small-molecule inhibitor of EPHB4 decreased cell viability in a timeand dose-dependent manner in 3 of the 4 cell lines tested. The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12%- 40% closure in treated vs. 60%-80% in untreated), with decreased phosphorylation of various tyrosyl-containing proteins, EphB4, and its downstream target p125FAK. Finally, in a xenograft tumor model, an EPHB4 inhibitor abrogated tumor growth by approximately 60% compared with untreated control. EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers.

AB - Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identi fi ed EPHB4 to be robustly overexpressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma, 82 adenocarcinoma, 25 dysplasia, 13 Barrett esophagus, and 25 adjacent or unrelated normal esophageal tissues were evaluated by immunohistochemistry. EPHB4 expression was signi ficantly higher in all the different histologic categories than in adjacent normal tissues. In 13 esophageal cancer cell lines, 3 of the 9 SCC cell lines and 2 of the 4 adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-nitroquinoline 1-oxide (4-NQO)-induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small-molecule inhibitor of EPHB4 decreased cell viability in a timeand dose-dependent manner in 3 of the 4 cell lines tested. The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12%- 40% closure in treated vs. 60%-80% in untreated), with decreased phosphorylation of various tyrosyl-containing proteins, EphB4, and its downstream target p125FAK. Finally, in a xenograft tumor model, an EPHB4 inhibitor abrogated tumor growth by approximately 60% compared with untreated control. EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers.

UR - http://www.scopus.com/inward/record.url?scp=84871962051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871962051&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0915

DO - 10.1158/0008-5472.CAN-12-0915

M3 - Article

C2 - 23100466

AN - SCOPUS:84871962051

VL - 73

SP - 184

EP - 194

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -